SVB Securities analyst Puneet Souda maintained a Buy rating on 908 Devices (MASS – Research Report) today and set a price target of $20.00. The company’s shares opened today at $7.51.
Souda covers the Healthcare sector, focusing on stocks such as Agilent, Illumina, and Thermo Fisher. According to TipRanks, Souda has an average return of -11.8% and a 37.83% success rate on recommended stocks.
Currently, the analyst consensus on 908 Devices is a Moderate Buy with an average price target of $18.50.
See the top stocks recommended by analysts >>
The company has a one-year high of $26.00 and a one-year low of $6.87. Currently, 908 Devices has an average volume of 292.5K.
Based on the recent corporate insider activity of 47 insiders, corporate insider sentiment is positive on the stock. This means that over the past quarter there has been an increase of insiders buying their shares of MASS in relation to earlier this year. Most recently, in November 2022, Kevin Hrusovsky, a Director at MASS bought 76,016.00 shares for a total of $26,605.60.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
908 Devices Inc manufactures medical devices. It has developed an innovative suite of purpose-built handheld and desktop mass spectrometry, or Mass Spec, devices for the point-of-need. Mass Spec devices are used at the point-of-need to interrogate unknown and invisible materials and provide quick, actionable answers to directly address some of the most critical problems in life sciences research, bioprocessing, industrial biotech, forensics and adjacent markets.
